138 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
www.fibrogen.com. www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans
8-K
EX-99.1
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the development
8-K
EX-99.1
5rfrknf3sv99
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
21xxuqn0k u5dgp
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
5gq egeroo
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
h52z8w279q0b ml20w
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
s5c184h xmji3vq
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
coo6nzd9m emchf
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
7tma2ne6a342kr3jw3j
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
fld7fuvlzq971tyr11
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
c35wnhpwhs7hw
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
mdj300j5gbewxjaagg
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm